Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
Identifieur interne : 004C03 ( Main/Merge ); précédent : 004C02; suivant : 004C04Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
Auteurs : Daniel Tarsy [États-Unis] ; Ross J. Baldessarini [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001B61
- to stream PascalFrancis, to step Curation: 001160
- to stream PascalFrancis, to step Checkpoint: 001B08
Links to Exploration step
Pascal:06-0289023Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Psychopharmacology Program, McLean Division of Massachusetts General Hospital</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0289023</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0289023 INIST</idno><idno type="RBID">Pascal:06-0289023</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B61</idno><idno type="wicri:Area/PascalFrancis/Curation">001160</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B08</idno><idno type="wicri:doubleKey">0885-3185:2006:Tarsy D:epidemiology:of:tardive</idno><idno type="wicri:Area/Main/Merge">004C03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Harvard Medical School</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Psychopharmacology Program, McLean Division of Massachusetts General Hospital</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term><term>Dyskinesia</term><term>Epidemiology</term><term>Extrapyramidal syndrome</term><term>Nervous system diseases</term><term>Neuroleptic</term><term>Risk factor</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Dyskinésie</term><term>Extrapyramidal syndrome</term><term>Epidémiologie</term><term>Facteur risque</term><term>Antipsychotique</term><term>Neuroleptique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></region><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004C03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:06-0289023
|texte= Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
}}
| This area was generated with Dilib version V0.6.23. |  |